logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

STARPLUS LEGEND (06683) will issue 6.64 million shares based on the share scheme.

date
21:43 06/08/2026
avatar
GMT Eight
Legendary Star (06683) announced that it will issue 6.64 million shares under its share scheme on August 6, 2026.
STARPLUS LEGEND (06683) announced that it will issue 6.64 million shares according to the share scheme on August 6, 2026.
Related Articles
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
HK Stock
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
HK Stock
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
HK Stock
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.